Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences (AKYA)
NASDAQ:AKYA
Holding AKYA?
Track your performance easily
AKYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.88 - $6.31
Previous Close$2.84
Volume126.18K
Average Volume (3M)192.96K
Market Cap
$140.58M
Enterprise Value$180.05M
Total Cash (Recent Filing)$45.22M
Total Debt (Recent Filing)$84.70M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Nov 04, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding49,499,487
10 Day Avg. Volume147,451
30 Day Avg. Volume192,957
Standard Deviation0.17
R-Squared0.16
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)6.31
Price to Sales (P/S)1.53
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$5.00Price Target Upside76.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Akoya Biosciences News
Bulls Say, Bears Say
Bulls Say
Market PositionAkoya has the largest (and rapidly growing) installed base in the spatial biology industry.
Operational EfficiencyThe completion of transitioning operations to the Company's new Center of Excellence (COE) in Marlborough, MA, which is now fully operational.
Product DemandAkoya's collaboration with Shanghai KR Pharmtech enabled regulatory approval of the PhenoImager HT in China.
Bears Say
Cash FlowAKYA ended Q2 with $49M of cash, compared to $62M of cash at Q1, and it's not abundantly clear how it'll achieve operating cash flow breakeven at year-end.
Financial PerformanceAKYA announced its third workforce reduction in 13 months, and lowered its 2024 revenue guidance in back-to-back quarters.
Investor ConcernsConcerns about the Board and management's repeated moves to cut headcount ahead of investing to grow the business, which gives concerns about employee morale and employee motivation levels.
---
Ownership Overview
39.28% Insiders
6.03% Mutual Funds
18.05% Other Institutional Investors
36.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKYA FAQ
What was Akoya Biosciences’s price range in the past 12 months?
Akoya Biosciences lowest stock price was $1.88 and its highest was $6.31 in the past 12 months.
What is Akoya Biosciences’s market cap?
Currently, no data Available
When is Akoya Biosciences’s upcoming earnings report date?
Akoya Biosciences’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Akoya Biosciences’s earnings last quarter?
Akoya Biosciences released its earnings results on Aug 05, 2024. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.266 by -$0.004.
Is Akoya Biosciences overvalued?
According to Wall Street analysts Akoya Biosciences’s price is currently Undervalued.
Does Akoya Biosciences pay dividends?
Akoya Biosciences does not currently pay dividends.
What is Akoya Biosciences’s EPS estimate?
Akoya Biosciences’s EPS estimate is -$0.2.
How many shares outstanding does Akoya Biosciences have?
Akoya Biosciences has 49,499,490 shares outstanding.
What happened to Akoya Biosciences’s price movement after its last earnings report?
Akoya Biosciences reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.266. Following the earnings report the stock price went down -6.512%.
Which hedge fund is a major shareholder of Akoya Biosciences?
Among the largest hedge funds holding Akoya Biosciences’s share is Fisher Asset Management LLC. It holds Akoya Biosciences’s shares valued at N/A.
---
Akoya Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (76.06% Upside)
$5.00 (76.06% Upside)
Blogger Sentiment
Bullish
AKYA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.01%
12-Months-Change
Fundamentals
Return on Equity
-128.20%
Trailing 12-Months
Asset Growth
-23.90%
Trailing 12-Months
Company Description
Akoya Biosciences
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
---
AKYA Earnings Call
Q2 2024
0:00 / 0:00
---
AKYA Stock 12 Month Forecast
Average Price Target
$5.00
▲(76.06% Upside)
Technical Analysis
Best Analysts Covering AKYA
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-28.71%
reiterated a buy rating 3 months ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -28.71% per trade.
---